1. DATE ISSUED  05/01/2019

1a. SUPERSEDES AWARD NOTICE dated except that any additions or restrictions previously imposed remain in effect unless specifically rescinded

2. CFDA NO.
93.946

3. ASSISTANCE TYPE  Cooperative Agreement

4. GRANT NO.  5 U01DP006213-04-00
Formerly  5U01DP006213-02

4a. FAIN  5U01DP006213

5. TYPE OF AWARD  Other

5a. ACTION TYPE  Non-Competing Continuation

6. PROJECT PERIOD  MM/DD/YYYY  MM/DD/YYYY
From  05/01/2016  Through  04/30/2021

7. BUDGET PERIOD  MM/DD/YYYY  MM/DD/YYYY
From  05/01/2019  Through  04/30/2020

8. TITLE OF PROJECT (OR PROGRAM)
COMPONENT A - MISSOURI PREGNANCY RISK ASSESSMENT MONITORING SYSTEM

9. GRANTEE NAME AND ADDRESS
HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF
PO BOX 570
MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES
Jefferson City, MO 65102-0570

10. GRANTEE AUTHORIZING OFFICIAL
Ms. Tonya R Loucks
920 WILLOW DR
Jefferson City, MO 65109-5796
Phone: 573-751-6014

11. APPROVED BUDGET (Excludes Direct Assistance)

<table>
<thead>
<tr>
<th>LANDAMOUNTSARESHOWNINUSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Amount of Federal Financial Assistance (from item 11a)</td>
</tr>
<tr>
<td>b. Less Unobligated Balance From Prior Budget Periods</td>
</tr>
<tr>
<td>c. Less Cumulative Prior Award(s) This Budget Period</td>
</tr>
<tr>
<td>d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION</td>
</tr>
<tr>
<td>e. Total Federal Funds Awarded to Date for Project Period</td>
</tr>
</tbody>
</table>

12. AWARD COMPUTATION

13. RECOMMENDED FUTURE SUPPORT
(Subject to the availability of funds and satisfactory progress of the project):

<table>
<thead>
<tr>
<th>YEAR</th>
<th>TOTAL DIRECT COSTS</th>
<th>YEAR</th>
<th>TOTAL DIRECT COSTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td></td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

14. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:
   a. DEDUCTION
   b. ADDITIONAL COSTS
   c. MATCHING
   d. OTHER RESEARCH (Add / Deduct Option)
   e. OTHER (See REMARKS)

15. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY OR THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:
   a. The grant program legislation.
   b. The grant program regulations.
   c. This award notice including terms and conditions, if any, noted below under REMARKS.
   d. Federal administrative requirements, cost principles and audit requirements applicable to the grant.

16. IN THE EVENT THERE ARE conflicting OR OTHERWISE INCONSISTENT POLICIES APPLICABLE TO THE GRANT, THE ABOVE ORDER OF PRECEDENCE SHALL PREVAIL. ACCEPTANCE OF THE GRANT TERMS AND CONDITIONS IS ACKNOWLEDGED BY THE GRANTEE WHEN FUNDS ARE DRAWN OR OTHERWISE OBTAINED FROM THE GRANT PAYMENT SYSTEM.

REMARKS  (Other Terms and Conditions Attached -  Yes  No)
This Notice approves the Core Comp A for $157,050; $21,799 in Mod A Opioid Quest.; $15,000 in Disability Category A; and $63,000 in Mod B Opioid Call Back Survey. Total Budgeted is $256,849.
<table>
<thead>
<tr>
<th>FY-ACCOUNT NO.</th>
<th>DOCUMENT NO.</th>
<th>ADMINISTRATIVE CODE</th>
<th>AMT ACTION FIN ASST</th>
<th>APPROPRIATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>24.a. 9-9390ATV</td>
<td>b. 16DP006213</td>
<td>c. DP</td>
<td>d. $84,799.00</td>
<td>e. 75-1819-0952</td>
</tr>
<tr>
<td>25.a. 9-9390B42</td>
<td>b. 16DP006213</td>
<td>c. DP</td>
<td>d. $15,000.00</td>
<td>e. 75-19-0844</td>
</tr>
<tr>
<td>26.a. 9-939ZREU</td>
<td>b. 16DP006213</td>
<td>c. DP</td>
<td>d. $157,050.00</td>
<td>e. 75-19-0948</td>
</tr>
</tbody>
</table>
1. Terms and Conditions - MO DHSS - DP6213-04 - FY19 NCC
**AWARD INFORMATION**

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Research awards at [https://www.cdc.gov/grants/federalregulationspolicies/index.html](https://www.cdc.gov/grants/federalregulationspolicies/index.html), the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number DP16-001, entitled *Pregnancy Risk Assessment Monitoring System (PRAMS)*, and application dated January 30, 2019, as may be amended, which are hereby made a part of this Research award hereinafter referred to as the Notice of Award (NOA).

Note: Due to grants management administration system parameters, the budget category names on Page 1 of this NOA may be altered from the budget categories submitted with the SF-424 Research and Related Budget application.

**Approved Funding:** Funding in the amount of **$256,849** is approved for the Year 04 budget period, which is **May 1, 2019** through **April 30, 2020**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

**Component/Project Funding:** The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

<table>
<thead>
<tr>
<th>NOFO Component</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core Component A</td>
<td>$157,050</td>
</tr>
<tr>
<td>Module A Opioid Questionnaire</td>
<td>$21,799</td>
</tr>
<tr>
<td>Disability Category A</td>
<td>$15,000</td>
</tr>
<tr>
<td>Module B Opioid Call Back Survey</td>
<td>$63,000</td>
</tr>
<tr>
<td><strong>Total Budget:</strong></td>
<td><strong>$256,849</strong></td>
</tr>
</tbody>
</table>

**Financial Assistance Mechanism:** Cooperative Agreement

**Substantial Involvement by CDC:** It is anticipated that CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

**Summary Statement/Technical Review Statement Response Requirement:** The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to and approved, in writing, by the Grants Management Specialist/Grants Management Officer (GMS/GMO) noted in
the Staff Contacts section of this NOA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, May 31, 2019, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Identify Project Being Reviewed in this PTR

<table>
<thead>
<tr>
<th>Project</th>
<th>Select</th>
</tr>
</thead>
<tbody>
<tr>
<td>DP16-001 Component A: Core PRAMS</td>
<td>☒</td>
</tr>
<tr>
<td>DP16-001 Component D: Family History of Breast and Ovarian Cancer Survey</td>
<td>☐</td>
</tr>
<tr>
<td>Supplement Module A: Opioid Questionnaire</td>
<td>☐</td>
</tr>
<tr>
<td>Supplement Module B: Opioid Call Back Survey</td>
<td>☐</td>
</tr>
</tbody>
</table>

*Conditions:
- Within 30 days of award, grantees should submit:
  1. Documentation demonstrating Elizabeth McCarthy has completed human subjects training.
  2. Time, as %FTE, Dr. Venkata Garikapaty (PI) dedicates to DP16-001 Component A: Core PRAMS to ensure completion of the PI/PD responsibilities outlined in the original Notice of Funding Opportunity Announcement.

Identify Project Being Reviewed in this PTR

<table>
<thead>
<tr>
<th>Project</th>
<th>Select</th>
</tr>
</thead>
<tbody>
<tr>
<td>DP16-001 Component A: Core PRAMS</td>
<td>☐</td>
</tr>
<tr>
<td>DP16-001 Component D: Family History of Breast and Ovarian Cancer Survey</td>
<td>☐</td>
</tr>
<tr>
<td>Supplement Module A: Opioid Questionnaire</td>
<td>☒</td>
</tr>
<tr>
<td>Supplement Module B: Opioid Call Back Survey</td>
<td>☐</td>
</tr>
</tbody>
</table>

*Conditions: Within 30 days of award, provide the time, as %FTE, the following staff will dedicate to Supplement Module A: Opioid Questionnaire:

  1. Dr. Venkata Garikapaty (PI)
  2. Dr. Rebecca Lander (PD)
  3. Elizabeth McCarthy, Senior Epidemiology Specialist
  4. Mary Mosley, Research Analyst III

Identify Project Being Reviewed in this PTR

<table>
<thead>
<tr>
<th>Project</th>
<th>Select</th>
</tr>
</thead>
<tbody>
<tr>
<td>DP16-001 Component A: Core PRAMS</td>
<td>☐</td>
</tr>
<tr>
<td>DP16-001 Component D: Family History of Breast and Ovarian Cancer Survey</td>
<td>☐</td>
</tr>
<tr>
<td>Supplement Module A: Opioid Questionnaire</td>
<td>☐</td>
</tr>
<tr>
<td>Supplement Module B: Opioid Call Back Survey</td>
<td>☒</td>
</tr>
</tbody>
</table>

*Conditions: Within 30 days of award provide the time, as %FTE, the following staff will dedicate to Supplement Module B: Opioid Call Back Survey:

  1. Dr. Venkata Garikapaty (PI)
  2. Dr. Rebecca Lander (PD)
  3. Elizabeth McCarthy, Senior Epidemiology Specialist
  4. Mary Mosley, Research Analyst III
**Restrictions:** A 10% ($6,300) funding restriction is placed on this award pending receipt of an IRB approval letter for Supplement Module B: Opioid Call Back Survey.

**Budget Revision Requirement:** By May 31, 2019 the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Staff Contacts section of this notice before the due date.

Within 30 days of award, provide the time, as %FTE, the following staff will dedicate to Component A: Core PRAMS; Supplement Module A: Opioid Questionnaire; and Supplement Module B: Opioid Call Back Survey.

- Dr. Venkata Garikapaty (PI)
- Dr. Rebecca Lander (PD)
- Elizabeth McCarthy, Senior Epidemiology Specialist
- Mary Mosley, Research Analyst III

**FUNDING RESTRICTIONS AND LIMITATIONS**

**Administrative Restriction(s):** Amendments and applications must be submitted using the Application Submission System & Interface for Submission Tracking (ASSIST) module which is a web-based service used for the preparation and submission of grant applications to CDC through eRA Commons. ASSIST provides the ability for applicants to prepare their applications online, and offers the applicant additional capabilities including the ability to preview the application image, validate the application against required business rules, and prepopulate data from an applicant organization's records, therefore identifying issues earlier in the application submission process.

For any assistance with submission through ASSIST, reach out to the eRA Help Desk.

**Human Subjects Restrictions:** Research involving human subjects cannot begin until a copy of the IRB approval letter is submitted to the Grants Management Specialist and approved by the Program office.

A. A funding restriction in the amount of $6,300 has been placed on this award in the Contractual BUDGET CATEGORY pending IRB approvals.

**Certificate of Confidentiality:** Institutions and investigators are responsible for determining whether research they conduct is subject to Section 301(d) of the Public Health Service (PHS) Act. Section 301(d), as amended by Section 2012 of the 21st Century Cures Act, P.L. 114-255 (42 U.S.C. 241(d)), states that the Secretary shall issue Certificates of Confidentiality (Certificates) to persons engaged in biomedical, behavioral, clinical, or other research activities in which identifiable, sensitive information is collected. In furtherance of this provision, CDC supported research commenced or ongoing after December 13, 2016 in which identifiable,
sensitive information is collected, as defined by Section 301(d), is deemed issued a Certificate and therefore required to protect the privacy of individuals who are subjects of such research. Certificates issued in this manner will not be issued as a separate document, but are issued by application of this term and condition to this award. See Additional Requirement 36 to ensure compliance with this term and condition. The link to the full text is at: 
https://www.cdc.gov/grants/additionalrequirements/ar-36.html

**Indirect Costs:**

Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 7, 2017, which calculates indirect costs as follows, a Provisional cost rate is approved at a rate of **21.4%** of the base, which includes Direct salaries and wages including fringe benefits exclusive of Group Insurance. The effective dates of this indirect cost rate are from July 1, 2018 to June 30, 2020.

**REPORTING REQUIREMENTS**

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Dwayne R. Cooper, Sr., Grants Management Specialist  
Centers for Disease Control and Prevention  
**Global Health Security Branch (GHSecB), Team 1**  
2960 Brandywine Road, NE MS E-15  
Atlants, Georgia 30341  
Email: dcooper1@cdc.gov (Include “Mandatory Grant Disclosures” in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include “Mandatory Grant Disclosures” in subject line) or  
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.
Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

**GENERAL REQUIREMENTS**

**HIV Program Review Panel Requirement:** All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Staff Contact section of this NOA.

**PAYMENT INFORMATION**

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application. All award funds must be tracked and reported separately.

The grant document number identified on the first page of the NOA must be known in order to draw down funds.

**Subaccount Title:** 16DP006213

**CDC STAFF CONTACTS**

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards. Many of the functions described in the GMO section are performed by the GMS, on behalf of the GMO.

**Grants Management Specialist Contact:**
Dwayne R. Cooper, Sr., Grants Management Specialist
Centers for Disease Control & Prevention
Global Health Security Branch (GHSecB), Team 1
2960 Brandywine Road, NE MS E-15
Atlanta, Georgia 30341
Telephone: (770) 488-2874
Email: dcooper1@cdc.gov
**Scientific Program Official/Project Officer:** The SPO is the federal official responsible for the programmatic, scientific, and/or technical aspects of grants and cooperative agreements.

**Programmatic Contact:**
**PO/SPO Contact:**
**Sue Shaw,** Scientific Program Official
Centers for Disease Control
National Center for Chronic Disease Prevention & Health
4770 Buford Highway
Chamblee, GA 30341
Telephone: 770-488-6142
Email: zgx7@cdc.gov

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NOA, including revisions to the NOA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization. GMO contact information appears on Page 1 of the NOA.

**Grants Management Officer Contact:**
**Angie N. Willard,** Team Lead
Centers for Disease Control and Prevention (CDC)
Office of Financial Resources (OFR)
Office of Grants Services (OGS)
Global Health Security Branch (GHSecB), Team 1
Email: aen4@cdc.gov
Office Number: (770) 488-2863